DirectorSeres Therapeutics, IncCambridge, MA, United States
Seres Therapeutics (Employee, Shareholder)
130 - Design and Preclinical Characterization of SER-155, an Investigational Cultivated Microbiome Therapeutic to Restore Colonization Resistance and Prevent Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
On Demand
LB15 - SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides difficile Infection (rCDI) after Standard-of-Care Antibiotics
Saturday, October 2, 20211:15 PM - 3:00 PM EDT
